However, tests of all the possible drug combinations with PD-1/PD-L1 inhibitors may exceed the number of eligible cancer patients who can be enrolled in clinical trials and are therefore not feasible in the context of clinical trials33. The gene discussed is PDCD1; the disease is cancer.